NewsBenzingaKodiak Sciences Says Phase 3 DAYBREAK Study Met Primary Endpoints With Zenkuda (Tarcocimab Tedromer) And Tabirafusp-ted (KSI-501) Showing Non-inferiority In Vision Gains For Wet Age-related Macular Degeneration Vs. Aflibercept At Year One Kodiak Sciences Says Phase 3 DAYBREAK Study Met Primary Endpoints With Zenkuda (Tarcocimab Tedromer) And Tabirafusp-ted (KSI-501) Showing Non-inferiority In Vision Gains For Wet Age-related Macular Degeneration Vs. Aflibercept At Year One Benzinga 2026.09.28 10:34 (GMT+0) Open on Benzinga Other news Signal restricts mobile screenshots as it confronts ‘existential threat’ of AI surveillance Why It’s Time to Buy the Pullback in Broadcom Stock A tale of two Nvidias These Are the Top 10 Largest IPOs Following Anthropic's Historic Market Debut Nvidia Has a New Problem, And It’s Not What You Think Tesla Begins FSD v15 Rollout to First-Wave Customers